# Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

> **NCT01151098** · PHASE3 · COMPLETED · sponsor: **Purdue Pharma LP** · enrollment: 189 (actual)

## Conditions studied

- Chronic Nonmalignant Pain

## Interventions

- **DRUG:** Buprenorphine transdermal patch

## Key facts

- **NCT ID:** NCT01151098
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2002-02
- **Final completion:** 2002-02
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2012-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01151098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01151098, "Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01151098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*